The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia

被引：0
|
作者：
Zeidan, Amer [1 ,2 ]
Esteve, Jordi [3 ]
Kim, Hee-Je [4 ]
Miyazaki, Yasushi [5 ]
Platzbecker, Uwe [6 ]
Schuh, Andre [7 ]
Westermann, Joerg [8 ]
Malek, Kamel [9 ]
Scott, Jeffrey [10 ]
Niolat, Julie [11 ]
Peyrard, Severine [11 ]
Kiertsman, Flavia [10 ]
Stegert, Mario [9 ]
Fenaux, Pierre [12 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Catholic Univ Korea, Catholic Hematol Hosp, Coll Med, Seoul, South Korea
[5] Nagasaki Univ, Nagasaki, Japan
[6] Univ Hosp Leipzig, Leipzig, Germany
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
[8] Charite Univ Med Ctr Berlin, Campus Virchow Clin, Berlin, Germany
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharma SAS, Rueil Malmaison, France
[12] Hop St Louis, Paris, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
acute myeloid leukemia; clinical trial; immunotherapy; myelodysplasia; AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-187
引用
收藏
页码：S188 / S188
页数：1
相关论文
共 50 条
  • [21] Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
    Mufti, Ghulam J.
    Silverman, Lewis R.
    Best, Steven
    Fructman, Steve
    Azarnia, Nozar
    Petrone, Michael E.
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [22] SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Shih, H. -C.
    Raju, A.
    Ogbonnaya, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    HAEMATOLOGICA, 2017, 102 : 489 - 489
  • [23] TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Shih, H-C.
    Raju, A.
    Ogbonnaya, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    HAEMATOLOGICA, 2017, 102 : 491 - 492
  • [24] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
    Seymour, John F.
    Silverman, Lewis R.
    Doehner, Hartmut
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Minden, Mark D.
    Stone, Richard M.
    Lucy, Lela M.
    Songer, Stephen
    Dougherty, Donna
    Hinkle, Randy
    Gambini, Dominique
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2015, 126 (23)
  • [25] SYSTEMATIC REVIEW OF THERAPY USED IN HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Bell, J.
    Galaznik, A.
    Huelin, R.
    Stokes, M.
    Seal, B.
    Fram, R.
    Faller, D. V.
    LEUKEMIA RESEARCH, 2017, 55 : S80 - S81
  • [26] STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
    Zeidan, Amer M.
    Giagounidis, Aristoteles
    Sekeres, Mikkael A.
    Xiao, Zhijian
    Sanz, Guillermo F.
    Van Hoef, Marlies
    Ma, Fei
    Hertle, Sabine
    Santini, Valeria
    FUTURE ONCOLOGY, 2022, 19 (09) : 631 - 642
  • [27] Counseling Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Regarding Expected Survival with Azacitidine (aza) Therapy: Are We Using Accurate Estimates?
    Deveaux, Michelle
    Stahl, Maximilian
    Giri, Smith
    Wang, Rong
    Podoltsev, Nikolai A.
    Ma, Xiaomei
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [28] Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
    Bewersdorf, Jan Philipp
    Hasle, Vanessa
    Shallis, Rory Michael
    Thompson, Ethan G.
    de Menezes, Daniel Lopes
    Rose, Shelonitda
    Boss, Isaac W.
    Halene, Stephanie
    Haferlach, Torsten
    Fox, Brian
    Zeidan, Amer M.
    BLOOD, 2022, 140 : 8910 - 8911
  • [29] The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Woodman, Richard C.
    Adesanya, Afoluso Ronnee
    Azarnia, Nozar
    Parris, Matthew
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [30] Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Adesanya, Afoluso Ronnee
    Zbyszewski, Patrick S.
    Woodman, Richard C.
    Fenaux, Pierre
    Silverman, Lewis R.
    BLOOD, 2019, 134
12345